The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis.
about
Herbal medicines and nonalcoholic fatty liver diseasePrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesRegression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver diseaseEffects of resveratrol in experimental and clinical non-alcoholic fatty liver diseaseCirculating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.Randomized double-blind placebo-controlled trial of powdered Brassica rapa ethanol extract on alteration of body composition and plasma lipid and adipocytokine profiles in overweight subjectsRisk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver diseaseTelmisartan attenuates hepatic fibrosis in bile duct-ligated rats.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?Knockdown of Astrocyte Elevated Gene-1 Inhibits Activation of Hepatic Stellate Cells.Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice.The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model MiceRegulation of hepcidin expression by inflammation-induced activin B.Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.Dipeptidylpeptidase--IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats.Fatty liver Shionogi-ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model.Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.Nootkatone confers hepatoprotective and anti-fibrotic actions in a murine model of liver fibrosis by suppressing oxidative stress, inflammation, and apoptosis.Regression of Nonalcoholic Fatty Liver Disease with Zinc and Selenium Co-supplementation after Disease Progression in Rats.
P2860
Q26738524-39AB7381-05DD-4C52-8E5F-A30CBF2ACF4FQ28272678-1665B38D-FA14-4B65-97EC-7E2FBD741F00Q28534290-39BD8E19-3B73-478F-B37B-6DF22C237301Q33563877-DE0E4902-FAF3-4080-9E43-128FCB119A5CQ34271108-D6F048EF-C947-41B1-B893-01B185C9293BQ36623078-5637067F-2289-49EB-8E41-3E8AB9B92133Q37596189-6AC900A6-963C-49EE-86F8-3B2D61238F50Q37727167-3BB6207E-D9ED-4A8D-B16F-2D1F14BCE8A1Q37837059-F3058CE0-E1FB-4EC3-BEF7-899F0136529CQ37863142-03D1678E-3D1C-4BCD-8299-175AF2E6603BQ38793998-4F6ACF75-E63D-48E9-AA68-44326AF5FF38Q39170768-FA62FDBC-7096-404A-95F2-6B7CD463A418Q41876453-D56E5BDC-8FC9-4F03-AABE-C38FEB077DC8Q41961541-FE17542B-4897-41B3-8CBF-343B6438C4EBQ42789129-789C5D61-5D38-4756-B5F4-E9FD9F0B917FQ43218274-15F329C1-DFF2-4656-9C6A-98960BCC3411Q44569053-B41C9972-6592-4033-97B7-3728D8003D19Q45805661-8F876BDC-E306-4942-BDD5-097688B9080AQ47320926-FC273EDA-73CA-4EFD-A1A1-9A35E74CEEC2Q49338731-E973F24B-8D26-41C4-9384-22C19E98FAA1
P2860
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The challenge of developing no ...... non-alcoholic steatohepatitis.
@en
The challenge of developing no ...... non-alcoholic steatohepatitis.
@nl
type
label
The challenge of developing no ...... non-alcoholic steatohepatitis.
@en
The challenge of developing no ...... non-alcoholic steatohepatitis.
@nl
prefLabel
The challenge of developing no ...... non-alcoholic steatohepatitis.
@en
The challenge of developing no ...... non-alcoholic steatohepatitis.
@nl
P2093
P2860
P1433
P1476
The challenge of developing no ...... non-alcoholic steatohepatitis.
@en
P2093
Detlef Schuppan
Michael Mark
Thomas Klein
P2860
P304
P356
10.1111/J.1478-3231.2010.02264.X
P577
2010-07-01T00:00:00Z